Effective half-lives for patients administered radiolabeled antibodies and calculated dose to the public in close proximity to patients.
Effective half-lives (T(e)) for radiolabeled antibodies can be much longer than that of traditional radiopharmaceuticals, potentially resulting in larger doses to members of the public. Clearance-rate data from patients treated with radio-labeled antibodies (RABs) were obtained from ten institutions. Calculations were made to determine if a single- or bi-exponential clearance-rate model was statistically justified; the results indicated that the former model was justified for more than 95% of the data. Values of T(e) for the different RABs are summarized. To plan actions to limit doses to less than 5 mSv annually for individuals continuously close to the patient (at 1 m), dose rates from patients at the time of release also are given as a function of T(e).
Kaurin
D G
DG
Vanderbilt University Medical Center, Radiation Oncology, Nashville, TN 37232-5671, USA. darryl.kaurin@mcmail.vanderbilt.edu
Carsten
A L
AL
Baum
J W
JW
D000911:Antibodies, Monoclonal; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D008297:Male; D008657:Metabolic Clearance Rate; D009369:Neoplasms / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D012984:Software; D013667:Technetium / Q000493:pharmacokinetics*
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D013667:Technetium